Comparative Pharmacology
Head-to-head clinical analysis: IDELALISIB versus VIJOICE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IDELALISIB versus VIJOICE.
IDELALISIB vs VIJOICE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idelalisib is a phosphoinositide 3-kinase (PI3K) delta isoform inhibitor. It inhibits the delta isoform of PI3K, which is selectively expressed in B-cells and plays a role in B-cell activation, proliferation, and survival. By blocking PI3K delta signaling, idelalisib reduces cell proliferation and induces apoptosis in malignant B-cells.
Phosphoinositide 3-kinase (PI3K) inhibitor that selectively inhibits PI3Kδ (delta isoform) with less activity against PI3Kγ. It blocks the PI3K/AKT/mTOR signaling pathway, reducing proliferation and survival of malignant B cells.
150 mg orally twice daily.
Adult: 200 mg orally twice daily, with or without food.
None Documented
None Documented
Clinical Note
moderateIdelalisib + Deslanoside
"Idelalisib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateIdelalisib + Acetyldigitoxin
"Idelalisib may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateIdelalisib + Ouabain
"Idelalisib may decrease the cardiotoxic activities of Ouabain."
Clinical Note
moderateIdelalisib + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Idelalisib."
Terminal elimination half-life approximately 8.2 hours; supports twice-daily dosing.
Terminal elimination half-life is approximately 50–100 hours. Due to this long half-life, steady-state is reached after about 2–3 weeks of daily dosing, allowing for once-daily administration.
Primary fecal (78%) with minor renal (14% unchanged) and biliary contribution.
Primarily biliary excretion (≈89% of dose recovered in feces as parent drug and metabolites). Renal excretion accounts for <2% of the dose as unchanged drug.
Category C
Category C
PI3K Inhibitor
PI3K Inhibitor